The Oncotyrol Prostate Cancer Outcome and Policy Model - How Latent Prevalence Affects the Benefit-Harm Balance of Screening

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.08.1843
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Prostate Cancer Mortality in Screen and Clinically Detected Prostate Cancer: Estimating the Screening Benefit

European Journal of Cancer
Cancer ResearchOncology
2010English

Long-Term Projections of the Harm-Benefit Trade-Off in Prostate Cancer Screening Are More Favorable Than Previous Short-Term Estimates

Journal of Clinical Epidemiology
Epidemiology
2011English

Cost-Effectiveness and Benefit-To-Harm Ratio of Risk-Stratified Screening for Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2018English

Prostate Cancer Screening: And the Pendulum Swings

Cancer
Cancer ResearchOncology
2018English

Screening for Prostate Cancer: How to Manage in 2006

Acta chirurgica iugoslavica
2005English

The Role of Modelling in the Policy Decision Making Process for Cancer Screening: Example of Prostate Specific Antigen Screening

Public Health Research and Practice
EnvironmentalPublic HealthOccupational Health
2019English

How Latent Viruses Cause Breast Cancer: An Explanation Based on the Microcompetition Model

Bosnian Journal of Basic Medical Sciences
Medicine
2018English

The Role of Prostate-Specific Antigen in Prostate Cancer Screening

Romanian Review of Laboratory Medicine
2014English

Prevalence and Factors Associated With the Performance of Prostate Cancer Screening in the Elderly: A Population-Based Study

Revista Brasileira de Geriatria e Gerontologia
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy